N-Terminal Pro-B-Type Natriuretic Peptide and Longitudinal Risk of Hypertension.
B-type natriuretic peptide
blood pressure
cohort studies
hypertension
natriuretic peptides
Journal
American journal of hypertension
ISSN: 1941-7225
Titre abrégé: Am J Hypertens
Pays: United States
ID NLM: 8803676
Informations de publication
Date de publication:
22 05 2021
22 05 2021
Historique:
received:
01
05
2020
revised:
21
08
2020
accepted:
23
12
2020
pubmed:
31
12
2020
medline:
15
12
2021
entrez:
30
12
2020
Statut:
ppublish
Résumé
Hypertension is a common condition that increases risk for future cardiovascular disease. N-terminal B-type natriuretic peptide (NT-proBNP) is higher in individuals with hypertension, but studies of its association with hypertension risk have been mixed. The REasons for Geographic And Racial Differences in Stroke (REGARDS) study enrolled 30,239 U.S. Black or White adults aged ≥45 years from 2003 to 2007. A subcohort included 4,400 participants who completed a second assessment in 2013-2016. NT-proBNP was measured by immunoassay in 1,323 participants without baseline hypertension, defined as blood pressure ≥140/90 or self-reported antihypertensive prescriptions. Two robust Poisson regression models assessed hypertension risk, yielding incidence rate ratios (IRRs): Model 1 included behavioral and demographic covariates and Model 2 added risk factors. A sensitivity analysis using a less conservative definition of hypertension (blood pressure ≥130/80 or self-reported antihypertensive prescriptions) was conducted. Four hundred and sixty-six participants developed hypertension after mean follow-up of 9.4 years. NT-proBNP was not associated with hypertension (Model 2 IRR per SD log NT-proBNP 1.01, 95% confidence interval 0.92-1.12), with no differences by sex, body mass index, age, or race. Similar findings were seen in lower-threshold sensitivity analysis. NT-proBNP was not associated with incident hypertension in REGARDS; this did not differ by race or sex.
Sections du résumé
BACKGROUND
Hypertension is a common condition that increases risk for future cardiovascular disease. N-terminal B-type natriuretic peptide (NT-proBNP) is higher in individuals with hypertension, but studies of its association with hypertension risk have been mixed.
METHODS
The REasons for Geographic And Racial Differences in Stroke (REGARDS) study enrolled 30,239 U.S. Black or White adults aged ≥45 years from 2003 to 2007. A subcohort included 4,400 participants who completed a second assessment in 2013-2016. NT-proBNP was measured by immunoassay in 1,323 participants without baseline hypertension, defined as blood pressure ≥140/90 or self-reported antihypertensive prescriptions. Two robust Poisson regression models assessed hypertension risk, yielding incidence rate ratios (IRRs): Model 1 included behavioral and demographic covariates and Model 2 added risk factors. A sensitivity analysis using a less conservative definition of hypertension (blood pressure ≥130/80 or self-reported antihypertensive prescriptions) was conducted.
RESULTS
Four hundred and sixty-six participants developed hypertension after mean follow-up of 9.4 years. NT-proBNP was not associated with hypertension (Model 2 IRR per SD log NT-proBNP 1.01, 95% confidence interval 0.92-1.12), with no differences by sex, body mass index, age, or race. Similar findings were seen in lower-threshold sensitivity analysis.
CONCLUSIONS
NT-proBNP was not associated with incident hypertension in REGARDS; this did not differ by race or sex.
Identifiants
pubmed: 33378421
pii: 6055606
doi: 10.1093/ajh/hpaa224
pmc: PMC8140656
doi:
Substances chimiques
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-483Subventions
Organisme : NINDS NIH HHS
ID : U01 NS041588
Pays : United States
Informations de copyright
© American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Stroke. 1997 May;28(5):936-40
pubmed: 9158628
Am J Hypertens. 2015 Oct;28(10):1262-6
pubmed: 25783741
J Aging Health. 1993 May;5(2):179-93
pubmed: 10125443
Hypertension. 2014 Mar;63(3):507-13
pubmed: 24324046
Am J Epidemiol. 2019 Mar 1;188(3):587-597
pubmed: 30452548
JAMA. 1992 Mar 4;267(9):1213-20
pubmed: 1586398
Am J Epidemiol. 1986 Sep;124(3):453-69
pubmed: 3740045
Clin Res Cardiol. 2016 May;105(5):421-31
pubmed: 26547915
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Clin Invest. 1994 May;93(5):1911-21
pubmed: 8182124
Circulation. 2016 Feb 16;133(7):631-8
pubmed: 26746175
Am Heart J. 1949 Feb;37(2):161-86
pubmed: 18107386
N Engl J Med. 1998 Jul 30;339(5):321-8
pubmed: 9682046
J Clin Hypertens (Greenwich). 2016 Aug;18(8):718-20
pubmed: 27507775
Hypertension. 2011 Apr;57(4):702-9
pubmed: 21383312
Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1529-35
pubmed: 16648193
J Am Geriatr Soc. 2017 Jan;65(1):83-90
pubmed: 27666895
Int J Cardiol. 2010 Jun 11;141(3):291-6
pubmed: 19157602
Hypertension. 2018 Jun;71(6):e13-e115
pubmed: 29133356
J Hypertens. 2013 Feb;31(2):370-6
pubmed: 23303356
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
JAMA Cardiol. 2018 Jan 1;3(1):11-17
pubmed: 29167879
Am J Cardiol. 2008 Feb 4;101(3A):3-8
pubmed: 18243856
Neuroepidemiology. 2005;25(3):135-43
pubmed: 15990444
Stroke. 2015 Mar;46(3):780-5
pubmed: 25628306
JAMA. 2017 Jan 10;317(2):165-182
pubmed: 28097354
JAMA. 2018 Oct 2;320(13):1338-1348
pubmed: 30285178
Front Nutr. 2015 Jan 19;1:29
pubmed: 25988129
Rev Esp Cardiol. 2004 May;57(5):396-402
pubmed: 15151773
Clin Exp Hypertens. 2015;37(2):148-54
pubmed: 24786840
Clin Chem. 2005 Mar;51(3):486-93
pubmed: 15738513
Hypertension. 2003 Apr;41(4):978-83
pubmed: 12623868